Research letter
Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study

https://doi.org/10.1016/j.jaad.2017.05.038Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (16)

  • Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery

    2021, Journal of the American Academy of Dermatology
    Citation Excerpt :

    A more recent retrospective analysis by Eilers et al2 investigated 1800 patients taking any form of oral anticoagulation while undergoing dermatologic surgery and demonstrated a 7-times higher likelihood of postoperative bleeding complications in patients taking DOACs compared with all other anticoagulation types combined.28 Despite the increased risk of bleeding complications with DOAC continuation, the authors of these studies recommended perioperative continuation of DOACs in dermatologic surgery, in accordance with existing dermatologic guidelines regarding other antithrombotic agents such as warfarin, aspirin, and clopidogrel.27-30 Historically, the risk of serious thrombotic events associated with perioperative interruption of warfarin or antiplatelet regimens during dermatologic surgery has been thought to outweigh the risk of limited harm (ie, bleeding complications) with their continuation.31-36

  • Optimizing Patient Safety in Dermatologic Surgery

    2019, Dermatologic Clinics
    Citation Excerpt :

    A separate study on rivaroxaban reported the benefit of continuing antithrombotic therapy with the caveat of a likely increased risk with complex flap closures.43 A more recent study involving dabigatran, apixaban, and rivaroxaban reported only occasional mild bleeding complications but showed no significant difference in poor outcomes between older and newer anticoagulants.44 However, many of the recent studies on new oral anticoagulants have small sample sizes, and further evaluation is warranted.

View all citing articles on Scopus

Funding sources: None.

Conflicts of interest: None declared.

Reprints not available from the authors.

View full text